Silence Therapeutics (SLN) EBT Margin (2020 - 2026)
Silence Therapeutics recorded quarterly EBT Margin of 3544.31% in Q1 2026, up 90.62% quarter-over-quarter from 37788.24% in Q4 2025, and up 1654724.0% year-over-year from N/an in Q1 2025.
Silence Therapeutics' EBT Margin history runs 7 years deep, the most recent figure standing at 3544.31% for Q1 2026.
- In Q1 2026, EBT Margin rose 1654724.0% year-over-year to 3544.31%; the TTM figure through Mar 2026 stood at 9338.16% (down 908212.0% YoY), while the FY2025 annual figure was 16042.75%, down 1593997.0% from the prior year.
- EBT Margin came in at 3544.31% for Q1 2026 at Silence Therapeutics, up from 37788.24% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 49.9% in Q4 2024 to a low of 37788.24% in Q4 2025.
- A 5-year average of 5626.93% and a median of 381.02% in 2023 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin soared 31376401 bps in 2022 and plunged 3783813 bps in 2025, its largest moves.
- Silence Therapeutics' EBT Margin stood at 315.84% in 2022, then slumped by 126 bps to 713.01% in 2023, then soared by 107 bps to 49.9% in 2024, then slumped by 75835 bps to 37788.24% in 2025, then jumped by 91 bps to 3544.31% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 3544.31%, 37788.24%, and 13180.5% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 18.99% |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 | -3,544.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,544.31% |
| Dec 31, 2025 | -37,788.24% |
| Sep 30, 2025 | -13,180.50% |
| Jun 30, 2025 | -13,672.00% |
| Mar 31, 2025 | -20,091.55% |
| Dec 31, 2024 | 49.90% |
| Sep 30, 2024 | -2,369.49% |
| Jun 30, 2024 | -2,582.94% |
| Mar 31, 2024 | -13.17% |
| Dec 31, 2023 | -713.01% |
| Sep 30, 2023 | -381.02% |
| Jun 30, 2023 | -131.92% |
| Mar 31, 2023 | -111.42% |
| Dec 31, 2022 | -315.84% |
| Sep 30, 2022 | -276.65% |
| Jun 30, 2022 | -368.38% |
| Mar 31, 2022 | -167.28% |
| Dec 31, 2021 | -328.85% |
| Sep 30, 2021 | -381.84% |
| Jun 30, 2021 | -470.49% |
| Mar 31, 2021 | -313,931.30% |
| Dec 31, 2020 | -240.55% |
| Sep 30, 2020 | -479,879.28% |